NIH to study Pfizer's Paxlovid in long Covid as demand — and infections — continue to fall
Pfizer’s Paxlovid will become the first treatment studied by the NIH for long Covid, the agency said Thursday.
The drug will be evaluated as part of the NIH’s $1 billion RECOVER program, with researchers trying to figure out the cause of the condition and a way to treat it. Currently, there are more than 200 symptoms associated with long Covid, including fatigue, pain, brain fog and irregular heartbeat, all of which can persist for months or years after Covid-19.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.